GILD Gilead Sciences Stock Outlook 2026: Yeztugo Launch Rewrites the HIV Playbook

Q1 2026: A $7 Billion Quarter That Silenced the Bears

Three years ago, the Gilead bull case rested almost entirely on Biktarvy holding the HIV franchise together while the oncology business found its footing. That narrative has fundamentally changed.

Q1 2026 total revenue hit $7.0 billion — 4% above the prior year — with product sales of $6.9 billion (+5% YoY). Biktarvy delivered $3.4 billion (+7%). Trodelvy jumped to $402 million (+37%). And a brand-new drug, Yeztugo, added $166 million in its first commercial quarter. The company raised full-year 2026 product sales guidance to $30.0B–$30.4B, $400 million above prior expectations.

The GAAP EPS of $(3.25)–$(2.85) looks alarming at first. It is not. The Arcellx acquisition ($7.8B equity) triggered $11.5 billion in acquired IPR&D charges under GAAP accounting rules — a one-time, non-cash item. Non-GAAP EPS guidance stands at $(1.05)–$(0.65), and the company’s cash generation remains intact.

Biktarvy: The $13+ Billion Annualized Machine

Biktarvy is not just Gilead’s biggest drug — it is one of the most commercially durable HIV treatments in history. Launched in 2018, it consistently grows despite being years into its commercial life. The $3.4B Q1 2026 implies an annualized run-rate above $13 billion if sequential trends hold.

The drug’s staying power comes from several structural factors. First, HIV treatment requires lifelong therapy, creating a captive, recurring revenue base. Second, Biktarvy’s once-daily, single-tablet regimen remains the standard of care for treatment-naive patients. Third, US patent protection extends to approximately 2033 — giving the franchise significant runway even against ViiV Healthcare’s long-acting injectable competition (Vocabria/Rekambys, bimonthly injection).

Medicare Part D negotiation risk exists under the Inflation Reduction Act, but Biktarvy’s biologics-adjacent status and relative pricing may offer some buffer compared to typical small-molecule drugs.

Yeztugo: The Twice-Yearly PrEP That Changes Everything

The FDA approved lenacapavir under the brand name Yeztugo on June 18, 2025, making it the first and only HIV pre-exposure prophylaxis (PrEP) option requiring only two injections per year.

The clinical case is extraordinary. The PURPOSE 1 trial, conducted primarily among cisgender women in sub-Saharan Africa, reported zero HIV infections in the lenacapavir arm, with statistically significant superiority over daily oral TDF/FTC (generic Truvada). PURPOSE 2 also reported positive topline results across a broader population including men who have sex with men and transgender women. These data supported the June 2025 FDA approval.

The commercial implication is direct: the single largest barrier to oral PrEP uptake is daily adherence. A twice-yearly clinic visit eliminates that barrier at the behavioral level. Prescriptions have ramped sharply, and Descovy (another Gilead PrEP product) also surged +38% in Q1 2026 to $807 million — suggesting the PrEP category itself is expanding.

Insurance access under Medicare Part D and commercial plans is the near-term critical variable. Early formulary placements have been favorable, per company commentary in Q1 2026 results.

BIC/LEN and Sunlenca: Lenacapavir Extends into Treatment

The lenacapavir story does not end with prevention. Two treatment applications are progressing:

Sunlenca (lenacapavir for HIV treatment) is already commercially approved for treatment-experienced adults with multidrug-resistant HIV. It is included in Gilead’s “Other HIV” revenue line.

BIC/LEN (bictegravir + lenacapavir oral combination) filed with the FDA under priority review. PDUFA target date: August 27, 2026. This once-weekly oral HIV treatment could become the next generation standard of care after Biktarvy, and Gilead would cannibalize itself — a position most pharma companies would envy.

Anito-Cel: The CAR-T Bet That Justifies the Arcellx Price Tag

The $7.8 billion Arcellx acquisition was controversial when announced. The logic becomes clearer as the asset matures.

Anito-cel (anitocabtagene autoleucel) is a BCMA-targeted CAR-T therapy designed for patients with relapsed or refractory multiple myeloma — one of the most aggressive blood cancers with high unmet need after prior lines of therapy. The FDA accepted the BLA with a PDUFA target date of December 23, 2026.

If approved, anito-cel would give Gilead presence in a multiple myeloma market currently dominated by Johnson & Johnson’s Carvykti and Bristol-Myers Squibb’s Abecma (both BCMA CAR-Ts). Differentiation on safety profile and manufacturing consistency will be key to carving out share.

Yescarta (axicabtagene ciloleucel, CD19 CAR-T for lymphoma) declined 14% to $332 million in Q1 2026. The CAR-T manufacturing bottleneck and competitive DLBCL landscape are real headwinds, but anito-cel in a different cancer type provides a diversification offset.

Trodelvy’s 37% Jump — An Oncology Business Coming of Age

At $402 million in Q1 2026 (+37% YoY), Trodelvy is no longer a rounding error. The growth driver is the expanding label in triple-negative breast cancer (TNBC). Combined with pembrolizumab (Keytruda) in PD-L1+ metastatic TNBC first-line therapy, Trodelvy demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in data presented in 2025.

Bladder cancer, non-small cell lung cancer, and additional solid tumor indications are in various trial stages. The antibody-drug conjugate (ADC) space is crowded — AstraZeneca/Daiichi Sankyo’s Enhertu has set a high clinical bar — but Trodelvy’s TROP-2 targeting addresses a different patient population and disease profile.

Annualized at Q1 run-rate, Trodelvy approaches $1.6 billion. A $2B year is plausible with label expansion.

Peer Comparison: Where GILD Sits in Big Pharma

Company	Market Cap	P/E	Dividend Yield	Key Growth Driver
GILD	$165.8B	18.2x	2.46%	HIV franchise + CAR-T
ABBV	~$310B	22x	~3.4%	Skyrizi/Rinvoq
MRK	~$250B	14x	~2.8%	Keytruda + Winrevair
LLY	~$750B	50x	~0.7%	GLP-1 Mounjaro/Zepbound
AMGN	~$160B	19x	~3.2%	Biosimilars + pipeline

GILD’s 18x P/E on trailing earnings, 2.46% dividend yield, and $152 analyst consensus target represent a value proposition relative to the sector — particularly given the multiple near-term catalysts (BIC/LEN August, anito-cel December).

See also: ABBV AbbVie outlook, MRK Merck outlook, AMGN Amgen outlook, JNJ Johnson & Johnson.

Three Price Scenarios for Year-End 2026

Bull Case — $165–$180: Anito-cel approved December 2026; BIC/LEN approved August 2026; Yeztugo achieves $900M+ annualized run-rate by Q4. Multiple expansion from 18x toward 22x on re-rating as a diversified biopharma. Jefferies $180 target within reach.

Base Case — $145–$160: BIC/LEN approved; anito-cel approval in line. Yeztugo ramps to $600–$700M annually. Trodelvy holds above $1.5B annual pace. Market re-rates GAAP EPS once the IPR&D charge clears. Consensus $152 target feels appropriate.

Bear Case — $100–$120: Anito-cel receives a Complete Response Letter (safety or manufacturing concern). ViiV’s bimonthly injectable begins materially eroding Biktarvy market share. IRA negotiations target Biktarvy pricing. The $78B Arcellx write-down becomes a cautionary tale.

Risk Factors

Risk	Probability	Mitigation
Anito-cel approval failure	Moderate	Phase 2/3 data positive, but CAR-T manufacturing CMC risk exists
Veklury revenue collapse	High (ongoing)	Already modeled in guidance; other products absorb
Lenacapavir access disputes	Low–Medium	Generic licensing in low-income countries underway
Biktarvy IRA price negotiation	Medium (2027+)	Long-acting alternatives in pipeline provide leverage
Integration costs from acquisitions	Medium	Arcellx, Ouro, Tubulis — three simultaneous integrations

Portfolio Fit: 401k, IRA, and Taxable Accounts

In a 401k or traditional IRA, GILD’s 2.46% dividend compounds tax-deferred. At current prices, $10,000 invested generates approximately $246 annually without immediate tax drag.

In a Roth IRA, the tax-free growth is most valuable for investors with long time horizons betting on anito-cel and BIC/LEN catalysts driving share appreciation.

In a taxable account, note that GILD qualifies as a qualified dividend payer, meaning dividends face the 0/15/20% long-term capital gains rate (based on income bracket) rather than ordinary income rates — a tax advantage over bond income.

GILD also appears in major healthcare ETFs. XLV (Health Care Select Sector SPDR) holds GILD as a top-10 position, offering indirect exposure without single-stock risk.

The Investment Thesis in One Sentence

Gilead in 2026 is a $30 billion revenue HIV monopolist launching its most disruptive product in a decade (Yeztugo), betting $7.8 billion on a CAR-T that faces its FDA verdict in December, and trading at an 18x earnings multiple that prices in very little of the upside — but also very little of the downside if anito-cel disappoints.

For investors comparing GILD with other biotech plays, see MRNA Moderna outlook, REGN Regeneron, and VRTX Vertex Pharmaceuticals.

---

This post is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making investment decisions.